Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01637415 · ClinicalTrials.gov registry record

The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS)

A clinical trial, sponsored by Stanford University.

Completed
Registry status
409
Enrollment target

NCT01637415: Completed study, sponsored by Stanford University.

NCT01637415 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 409 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01637415 has completed, sponsored by Stanford University.

COMPLETED
Registry status
409 participants
Enrollment target

Study Summary

Although there are several tools that can be used to evaluate the severity of ongoing alcohol withdrawal syndrome (AWS), there is no available tool that can predict which patients are at risk for developing AWS at the time admission, before the patient has developed AWS. Unfortunately, there are severe symptoms of alcohol withdrawal (e.g., seizures) which may develop early in the hospitalization, and before the development of other systemic symptoms which may warn medical personnel of the possibility of impeding alcohol withdrawal (e.g., autonomic instability, delirium). The goal of this study is to evaluate the psychometric properties (e.g., predictive validity) of a new tool, the Prediction of Alcohol Withdrawal Severity Scale (PAWSS), on identifying which patients are at risk for developing complicated AWS (i.e., seizures, hallucinosis, delirium tremens) among hospitalized, medically ill patients.

Primary Outcome

Complicated withdrawal will be defined as patients meeting criteria for complicated or severe withdrawal according to DSM-IV-Tr, a CIWA-Ar score \> or = to 15, or experiencing severe symptoms requiring the use of benzodiazepine agents for symptom management.

Trial Details

FieldValue
Enrollment Target 409 participants
Start Date 2012-05
Est. Completion 2014-06
Stanford University

1,744 total trials

What the finished NCT01637415 record still lists

NCT01637415 is an observational study that tracks outcomes without assigning an intervention. The registered 409 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT01637415 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01637415 about?

NCT01637415 is a clinical study titled "The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS)". Although there are several tools that can be used to evaluate the severity of ongoing alcohol withdrawal syndrome (AWS), there is no available tool that can predict which patients are at risk for developing AWS at the time admission, before the patient has developed AWS. Unfortunately, there are sev...

What is the current status of trial NCT01637415?

This trial is currently completed. The enrollment target is 409 participants. The study started on 2012-05. Estimated completion is 2014-06.

Who is sponsoring clinical trial NCT01637415?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06717334 · 409 participants

    A Study of Lung Cancer Screening in People With Unexplained Weight Loss

  • NCT02043691 · 410 participants · NA

    Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies

  • NCT03042975 · 410 participants

    Imaging Genetics of Laryngeal Dystonia

  • NCT05730036 · 410 participants · Phase 3

    A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01637415, the US trial registry maintained by the National Library of Medicine. NCT01637415 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.